This week, a World Health Organization official warned that A. Covid-19 A vaccine is not necessarily a “silver bullet” to end an epidemic.
“There is some light at the end of a long tunnel, but these vaccines are not a silver bullet that will end the epidemic in the near future,” said Takeshi Kasai, WHO regional director for the Western Pacific region, on Thursday. South China Morning Newspaper.
“This means that we are all tired of this epidemic, we must stick to Actions and behaviors that protect Not only ourselves but also those around us: hand washing, Wearing a maskAnd the Physical distancing And avoid places with a high risk of transmission. ”
The World Health Organization has recommended that groups at risk – those 60 years of age or older and those with underlying health problems – prioritize initial doses of the vaccine. Kasai noted that if “the right size and type of investment” are made, there must be “appropriate doses to vaccinate high-priority populations in all countries around the world” by the end of 2021.
He continued: “For others, other than those at-risk groups, we may look for another 12 to 24 months before the majority of people receive this vaccine, and even then, there is some uncertainty and unknown.”
In the United States, Dr. Anthony Fauci, the nation’s top infectious disease expert, He said on Monday He expects the country to see herd immunity by late spring or early summer after coronavirus vaccines become widely available.
“By the time we reach autumn, we can start approaching a certain degree of comfort where the level of infection is very low in the community,” he said, “We can basically start approaching some form of normalcy,” although noting that Wearing masks and other precautionary measures are likely to continue “after several months from the second half and beyond 2021”.
For now, the US Food and Drug Administration (FDA) has granted emergency approval for a COVID-19 vaccine developed by Pfizer and BioNTech. Health care workers, residents, and long-term care facility staff began receiving vaccinations this week. Another promising candidate developed by Moderna will likely receive approval for emergency use as early as this week.
A third filter, from Johnson & Johnson, which requires only one dose, works its way through the pipeline. Behind that is a filter from AstraZeneca and the University of Oxford. American health experts hope that the combination of vaccines will eventually enable the United States to weather the outbreak.
The Associated Press contributed to this report.